Figure 1.
PRIMA‐1 selectively inhibits the proliferation of esophageal squamous cell carcinoma (ESCC) cell lines with TP53 missense mutations. A, Total p53 protein levels were evaluated by western blot analysis. B, PRIMA‐1 dose‐response curves for ESCC cell lines after 48 h of treatment with PRIMA‐1 using the MTT cell viability assay; n = 3‐5. Error bars show the standard deviation. C, IC 50 values of PRIMA‐1 in ECSS cell lines. D, IC 50 values of PRIMA‐1, cisplatin, docetaxel, doxorubicin and 5‐fluorouracil in ESCC with TP53 missense mutation vs frameshift/nonsense mutation and wild‐type ESCC cells. ***P < .001